Eisai Transfers Rights to Receive Royalties Outside of Japan for EZH2 Inhibitor Tazemetostat to Royalty Pharma
- Written by ACN Newswire - Press Releases
Tazemetostat is a first-in-class, oral EZH2 inhibitor discovered by Epizyme,
Read more //?#
.
Why Middle Australia Is Quietly Driving the Shift Away From Car Ownership
The narrative around changing attitudes to car ownership has long focused on Gen Z. Younger Australians are often portrayed as the generation movi...
Launchd Acquires WeAreTENZING as ANZ Creator Economy Spend Nears $1 Billion
Launchd, Australia's leading talent-first creator economy group, has acquired WeAreTENZING, one of New Zealand's most respected talent agencies, b...
Time to punch above our weight and stop shadowboxing on AI
Australia prides itself on being an innovation economy. We celebrate startups, talk about productivity, and lean into our reputation for punching ...
Colter Bay Capital Launches as Australia’s Newest Institutional Private Credit Fund
Led by seasoned capital markets veteran Mark Wang, the fund is purpose-built to serve Australia’s most productive yet chronically underserved busi...
Global Thryv voices bring a sharper lens to International Women’s Day
Thryv® (NASDAQ: THRY), ANZ’s leading AI-enabled small business marketing software platform provider, marks International Women’s Day (IWD) with a bu...
AI curiosity fuels new wave of employee-led innovation in Australia
Leaders across Australia are asking themselves how they can ensure their employees get the most out of AI. We recently conducted research to help an...